JP2015522551A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522551A5 JP2015522551A5 JP2015514226A JP2015514226A JP2015522551A5 JP 2015522551 A5 JP2015522551 A5 JP 2015522551A5 JP 2015514226 A JP2015514226 A JP 2015514226A JP 2015514226 A JP2015514226 A JP 2015514226A JP 2015522551 A5 JP2015522551 A5 JP 2015522551A5
- Authority
- JP
- Japan
- Prior art keywords
- alk
- haloalkoxy
- haloalkylthio
- cancer
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000006684 polyhaloalkyl group Polymers 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000012453 solvate Substances 0.000 claims description 22
- 125000003545 alkoxy group Chemical group 0.000 claims description 21
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 239000000651 prodrug Substances 0.000 claims description 20
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 19
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 18
- 125000004995 haloalkylthio group Chemical group 0.000 claims description 17
- 125000003118 aryl group Chemical group 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 10
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 10
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 10
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 7
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 2
- SXPRVMIZFRCAGC-UHFFFAOYSA-N 1,2,3,4,5-pentafluoro-6-methylbenzene Chemical compound CC1=C(F)C(F)=C(F)C(F)=C1F SXPRVMIZFRCAGC-UHFFFAOYSA-N 0.000 claims description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 claims description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229940126208 compound 22 Drugs 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 2
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- -1 C 1-6 polyhaloalkoxy Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 description 10
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 241001024304 Mino Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651757P | 2012-05-25 | 2012-05-25 | |
| US61/651,757 | 2012-05-25 | ||
| PCT/US2013/042689 WO2013177534A2 (en) | 2012-05-25 | 2013-05-24 | New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018021248A Division JP6543366B2 (ja) | 2012-05-25 | 2018-02-08 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522551A JP2015522551A (ja) | 2015-08-06 |
| JP2015522551A5 true JP2015522551A5 (cg-RX-API-DMAC10.html) | 2016-07-14 |
| JP6290871B2 JP6290871B2 (ja) | 2018-03-07 |
Family
ID=49624538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514226A Expired - Fee Related JP6290871B2 (ja) | 2012-05-25 | 2013-05-24 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
| JP2018021248A Expired - Fee Related JP6543366B2 (ja) | 2012-05-25 | 2018-02-08 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018021248A Expired - Fee Related JP6543366B2 (ja) | 2012-05-25 | 2018-02-08 | 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9650399B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2854819B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6290871B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN105120854B (cg-RX-API-DMAC10.html) |
| BR (1) | BR112014029439A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2874057A1 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1218709A1 (cg-RX-API-DMAC10.html) |
| RU (1) | RU2641903C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2013177534A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
| ES2764279T3 (es) * | 2014-05-30 | 2020-06-02 | Governing Council Univ Toronto | Compuestos de sulfonamida y su uso como inhibidores de stat5 |
| JP2020505457A (ja) * | 2017-01-23 | 2020-02-20 | ユニヴァーシティ オブ ハワイＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｈａｗａｉｉ | ２−アリールスルホンアミド−Ｎ−アリールアセトアミド誘導体化Ｓｔａｔ３ |
| EP3898582A4 (en) * | 2018-12-21 | 2022-08-24 | The Governing Council of the University of Toronto | NEW SALICYLIC ACID DERIVATIVES, PHARMACEUTICALLY APPROVED SALT THEREOF, COMPOSITION THEREOF, AND METHODS OF USE THEREOF |
| CA3135802A1 (en) | 2019-04-05 | 2020-10-08 | Kymera Therapeutics, Inc. | Stat degraders and uses thereof |
| CN114761013A (zh) | 2019-09-27 | 2022-07-15 | 迪斯克医药公司 | 治疗骨髓纤维化和相关病症的方法 |
| EP4114377A4 (en) * | 2020-03-05 | 2024-04-24 | Centessa Pharmaceuticals (UK) Limited | STAT-INHIBITING COMPOUNDS AND COMPOSITIONS |
| CN115551490A (zh) * | 2020-03-05 | 2022-12-30 | 詹皮克斯有限公司 | α取代的STAT抑制剂及其组合物 |
| JP2023528223A (ja) | 2020-05-13 | 2023-07-04 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症を処置するための抗ヘモジュベリン（ｈｊｖ）抗体 |
| CN112941036B (zh) * | 2021-02-08 | 2023-06-09 | 吉林惠康生物药业有限公司 | 一种提高狂犬病毒在人二倍体细胞中复制水平的方法 |
| CN114751927B (zh) * | 2022-03-08 | 2023-10-31 | 中山大学 | 一种硼酸化合物、制备方法及用途 |
| CN118994047A (zh) * | 2024-08-13 | 2024-11-22 | 中国药科大学 | 一种水杨醛衍生物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603565A (zh) * | 2003-12-11 | 2012-07-25 | 得克萨斯州大学系统董事会 | 治疗细胞增殖疾病的化合物 |
| ES2533383T3 (es) * | 2006-03-31 | 2015-04-09 | The Board Of Regents Of The University Of Texas System | Fármacos anticancerosos biodisponibles por vía oral relacionados con ácido cafeico |
| WO2007136858A2 (en) | 2006-05-19 | 2007-11-29 | H. Lee Moffitt Cancer Center & Research Institute | Small molecule inhibitors of stat3 with anti-tumor activity |
| UA95978C2 (ru) * | 2006-10-02 | 2011-09-26 | Оцука Фармас'Ютікел Ко., Лтд. | Ингибитор активации stat3/5 |
| EP2325181B1 (en) * | 2008-07-10 | 2017-03-29 | General Incorporated Association Pharma Valley Project Supporting Organisation | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient |
| WO2010117438A2 (en) | 2009-04-06 | 2010-10-14 | University Of Central Florida Research Foundation, Inc. | Compounds that suppress cancer cells and exhibit antitumor activity |
| US8846707B2 (en) * | 2010-08-02 | 2014-09-30 | Univeristy Of Central Florida Research Foundation, Inc. | Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of stat protein |
| EP2975936A4 (en) * | 2013-03-22 | 2017-03-15 | University of Hawaii | Novel stat3 inhibitors |
-
2013
- 2013-05-24 RU RU2014152697A patent/RU2641903C2/ru not_active IP Right Cessation
- 2013-05-24 CA CA2874057A patent/CA2874057A1/en not_active Abandoned
- 2013-05-24 CN CN201380038486.1A patent/CN105120854B/zh not_active Expired - Fee Related
- 2013-05-24 EP EP13794722.2A patent/EP2854819B1/en active Active
- 2013-05-24 BR BR112014029439A patent/BR112014029439A2/pt not_active Application Discontinuation
- 2013-05-24 CN CN201910222566.1A patent/CN110003104A/zh active Pending
- 2013-05-24 HK HK16106053.3A patent/HK1218709A1/zh unknown
- 2013-05-24 US US14/550,293 patent/US9650399B2/en not_active Expired - Fee Related
- 2013-05-24 WO PCT/US2013/042689 patent/WO2013177534A2/en not_active Ceased
- 2013-05-24 JP JP2015514226A patent/JP6290871B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-30 US US15/475,108 patent/US10377780B2/en active Active
-
2018
- 2018-02-08 JP JP2018021248A patent/JP6543366B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-25 US US16/451,883 patent/US20190382422A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015522551A5 (cg-RX-API-DMAC10.html) | ||
| JP2018109017A5 (cg-RX-API-DMAC10.html) | ||
| MX2021013472A (es) | Moduladores de thr-? y metodos de uso de estos. | |
| RU2014152697A (ru) | Новые производные салициловой кислоты, их фармацевтически приемлемая соль, композиции и способ применения | |
| PT1613315E (pt) | Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias | |
| HK1211289A1 (en) | Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| EA200601350A1 (ru) | Азотсодержащие гетероциклические производные и их фармацевтические применения | |
| WO2009120660A3 (en) | Substituted pyridoxazines | |
| EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
| PH12018550049A1 (en) | Protein kinase inhibitor, preparation method and medical use thereof | |
| MX2010001189A (es) | Derivados de naftiridina como modulares del canal de potasio. | |
| MX2008016134A (es) | Derivados de fenol para el tratamiento de enfermedades respiratorias. | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
| WO2012107706A8 (en) | Phenothiazine diaminium salts and their use | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| WO2008012635A3 (en) | Amine derivatives useful as anticancer agents | |
| MX2009006742A (es) | Inhibidores acilaminopirazoles como fgfr. | |
| TW200628154A (en) | Organic compounds | |
| JP2012530779A5 (cg-RX-API-DMAC10.html) | ||
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| JP2019521958A5 (cg-RX-API-DMAC10.html) | ||
| JP2018530582A5 (cg-RX-API-DMAC10.html) | ||
| WO2012131656A3 (en) | Compounds for use as therapeutic agents affecting p53 expression and/or activity | |
| WO2007024843A3 (en) | Pyrimidinyl-pyrazole inhibitors of aurora kinases |